Hypericin in the Dark: Foe or Ally in Photodynamic Therapy?
Photosensitizers (PSs) in photodynamic therapy (PDT) are, in most cases, administered systemically with preferential accumulation in malignant tissues; however, exposure of non-malignant tissues to PS may also be clinically relevant, when PS molecules affect the pro-apoptotic cascade without illumin...
Main Authors: | Veronika Huntosova, Katarina Stroffekova |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/8/10/93 |
Similar Items
-
Hypericin, a potential new BH3 mimetic
by: Anastasia Doroshenko, et al.
Published: (2022-10-01) -
Photodynamic therapy – hypericin tetraether liposome conjugates and their antitumor and antiangiogenic activity
by: Nikola Plenagl, et al.
Published: (2019-01-01) -
Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins
by: Peter Ferenc, et al.
Published: (2011-11-01) -
Facile fabrication of hypericin-entrapped glyconanoparticles for targeted photodynamic therapy
by: Shao C, et al.
Published: (2018-07-01) -
Bilayer Dissolving Microneedles Incorporating Hypericin-Loaded Nanocapsules For Improved Localised Photodynamic Therapy
by: Heba M. Abd-El-Azim, et al.
Published: (2019-04-01)